The US market for cystic fibrosis (CF) is projected to exceed $896 million by 2015. Largely driven by the sales of two leading drugs, Pulmozyme and TOBI, the market is expected to further expand significantly over the coming years, given the successful launch of novel and enhanced drug formulations or therapies including new mucolytic drugs, pancreatic enzyme replacement drugs, anti-inflammatory drugs, and drugs targeting genetic CFTR defects.

Cystic fibrosis is one of the most common genetic disorders in the US. The US is home to about 30,000 cystic fibrosis patients, with more than 2,000 cases being diagnosed every year. Although improved approaches in symptomatic treatment over the years have increased the survival rate of patients, there exist no specific disease-modifying drug or drugs targeting the underlying cause of the disease or for curing the disease. Therapeutic interventions in addressing the underlying cause of cystic fibrosis continue to evolve, driven by the need for effective, cutting-edge intervention techniques that restore Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene function, while simultaneously ensuring patient comfort, and improving patients' quality of life.

According to Global Industry Analysts, Pulmozyme and TOBI dominate the US market for Cystic Fibrosis drugs. Pulmozyme® works by breaking up the thickened airway secretions, while TOBI® is an inhaled antibiotic indicated for the treatment of lung infections caused by Pseudomonas aeruginosa (Pa) in cystic fibrosis patients. However, Pulmozyme is facing stiff competition from hypertonic saline, which represents a cost-effective option of clearing sputum from the lungs of cystic fibrosis patients. The market is expected to further expand significantly over the coming years, given the successful launch of novel and promising enhanced drug formulations or therapies, including new mucolytic drugs, pancreatic enzyme replacement drugs, anti-inflammatory drugs, and drugs targeting genetic CFTR defects currently in pipeline.

This report analyzes the US market for Cystic Fibrosis in Millions of US$. Annual estimates and forecasts are provided for the period of 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Axcan Pharma, Inc., Digestive Care, Inc., Gilead Sciences, Inc., Eurand N.V., Inspire Pharmaceuticals, Inc., KaloBios Pharmaceuticals, Inc., Nektar Therapeutics, PTC Therapeutics, Inc., Transave, Inc., Vertex Pharmaceuticals, Inc., Actelion Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, and Pharmaxis Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Global Industry Analysts ©

Click for report details: Cystic Fibrosis - A US Market Report&